Piramal Enterprises Limited announced that the Supreme Court has exempted its popular painkiller Saridon from the list of banned fixed-dose combinations (FDCs). Saridon, which is amongst the most widely distributed analgesic tablets in India, was banned by the government expert committee based on the formulation and ingredients.
The last year, in September, Supreme Court stayed the ban allowing the continuation of manufacturing, distribution, and sale of analgesic brand Saridon.
Nandini Piramal, Executive Director, Piramal Enterprises Limited said, “Saridon is a heritage brand trusted by customers for the last 50 years in India. This exemption from the banned list of FDCs validates our intent to serve our customers with the highest levels of integrity.”
She is a stock exchange filing, added, “We continue to expand our healthcare product portfolio with an aim to be amongst the top three OTC (over-the-counter) product companies in India by 2020.” Piramal also said that they were confident that the law would prevail in their favour.
The government, last September had banned 328 FDCs, which were termed as ‘irrational’ on the basis of safety issues and lack of therapeutic justification.
Read EquityPandit’s Technical Analysis of Nifty Pharma